

# Bettina E Hansen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1326109/bettina-e-hansen-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152  
papers

11,309  
citations

54  
h-index

104  
g-index

158  
ext. papers

12,925  
ext. citations

6.6  
avg, IF

5.65  
L-index

#	Paper	IF	Citations
152	Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 2584-93	27.4	1089
151	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. <i>Lancet, The</i> , <b>2005</b> , 365, 123-9	40	948
150	Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. <i>Gastroenterology</i> , <b>2009</b> , 136, 1281-7	13.3	311
149	Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. <i>Gastroenterology</i> , <b>2008</b> , 135, 459-67	13.3	301
148	Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. <i>Gastroenterology</i> , <b>2009</b> , 137, 2002-9	13.3	300
147	Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. <i>Hepatology</i> , <b>2004</b> , 39, 804-10	11.2	287
146	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. <i>Hepatology</i> , <b>2004</b> , 39, 500-8	11.2	267
145	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <i>Gastroenterology</i> , <b>2014</b> , 147, 1338-49.e5; quiz e15	13.3	265
144	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , <b>2008</b> , 47, 1856-62	11.2	226
143	Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. <i>Hepatology</i> , <b>2010</b> , 52, 1251-7	11.2	225
142	Comparison of echocardiographic methods with magnetic resonance imaging for assessment of right ventricular function in children. <i>American Journal of Cardiology</i> , <b>1995</b> , 76, 589-94	3	225
141	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
140	Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 297-303	0.7	203
139	Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. <i>Journal of Hepatology</i> , <b>1997</b> , 26, 961-6	13.4	193
138	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. <i>Hepatology</i> , <b>2010</b> , 52, 454-61	11.2	188
137	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , <b>2013</b> , 58, 872-80	11.2	163
136	Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). <i>Gut</i> , <b>2014</b> , 63, 292-9	19.2	162

135	Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2010</b> , 139, 491-8	13.3	156
134	Quantification of right ventricular function with magnetic resonance imaging in children with normal hearts and with congenital heart disease. <i>American Heart Journal</i> , <b>1995</b> , 130, 828-37	4.9	153
133	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. <i>Journal of Virological Methods</i> , <b>2003</b> , 110, 201-9	2.6	152
132	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , <b>2015</b> , 64, 1289-95	19.2	146
131	Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 1305-11	13.4	144
130	Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. <i>Gastroenterology</i> , <b>2012</b> , 142, 513-520.e1	13.3	134
129	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1006-1011	13.4	133
128	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , <b>2013</b> , 62, 760-5	19.2	132
127	Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , <b>2011</b> , 54, 443-51	11.2	132
126	External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 1201-4	6.9	128
125	Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2044-50	0.7	128
124	Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. <i>Gastroenterology</i> , <b>1999</b> , 117, 408-13	13.3	128
123	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 250-7	13.4	127
122	Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 449-54	13.4	117
121	Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 415-8	7	107
120	Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. <i>Gastroenterology</i> , <b>2010</b> , 139, 1934-41	13.3	104
119	Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 493-500	13.4	96
118	A randomized comparison of electrocautery incision with Savary bougienage for relief of anastomotic gastroesophageal strictures. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 70, 849-55	5.2	93

117	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 498-510	35.1	89
116	Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. <i>Hepatology</i> , <b>2007</b> , 46, 388-94	11.2	87
115	Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 163-70	2.2	85
114	Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 192-8	13.4	75
113	Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. <i>Gastroenterology</i> , <b>2018</b> , 154, 515-517.e3	13.3	71
112	A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1762-9	0.7	71
111	The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , <b>2010</b> , 52, 1334-40	11.2	71
110	Metastases in supraclavicular lymph nodes in lung cancer: assessment with palpation, US, and CT. <i>Radiology</i> , <b>2004</b> , 232, 75-80	20.5	70
109	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 539-46	13.4	66
108	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , <b>2012</b> , 56, 67-75	11.2	64
107	Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 468-76	13.4	64
106	Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 137-44	13.4	61
105	Serum liver enzymes are associated with all-cause mortality in an elderly population. <i>Liver International</i> , <b>2014</b> , 34, 296-304	7.9	59
104	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. <i>Liver International</i> , <b>2012</b> , 32, 622-8	7.9	58
103	Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , <b>2012</b> , 36, 641-7	5.6	58
102	Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfecting with HBV and HIV. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 974-80	7	57
101	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. <i>Hepatology</i> , <b>2006</b> , 44, 721-7	11.2	57
100	Histological features in western patients with idiopathic non-cirrhotic portal hypertension. <i>Histopathology</i> , <b>2013</b> , 62, 1083-91	7.3	56

99	Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. <i>Liver Transplantation</i> , <b>2010</b> , 16, 837-46	4.5	55
98	Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon- $\alpha$ 2b: relation to response and HBV genotype. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 9-17	1.6	54
97	A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 292-4	7	54
96	Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. <i>BMC Gastroenterology</i> , <b>2003</b> , 3, 33	3	53
95	Volume measurements of the anal sphincter complex in healthy controls and fecal-incontinent patients with a three-dimensional reconstruction of endoanal ultrasonography images. <i>Diseases of the Colon and Rectum</i> , <b>2005</b> , 48, 540-8	3.1	49
94	Endoscopic visible light spectroscopy: a new, minimally invasive technique to diagnose chronic GI ischemia. <i>Gastrointestinal Endoscopy</i> , <b>2011</b> , 73, 291-8	5.2	47
93	A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , <b>2011</b> , 51, 175-8	14.5	45
92	Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Hepatology</i> , <b>2010</b> , 52, 1225-31	11.2	45
91	MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1231-8	13.4	44
90	US and fluoroscopic-guided percutaneous jejunostomy: experience in 49 patients. <i>Journal of Vascular and Interventional Radiology</i> , <b>2000</b> , 11, 101-6	2.4	44
89	Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 962-72	2.4	43
88	Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. <i>BMC Gastroenterology</i> , <b>2004</b> , 4, 13	3	42
87	Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. <i>Gastrointestinal Endoscopy</i> , <b>2008</b> , 67, 821-7	5.2	41
86	Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 898-903	13.4	40
85	The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. <i>Quality of Life Research</i> , <b>2004</b> , 13, 1469-81	3.7	39
84	Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 256-62	13.4	39
83	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 649-657	18.8	38
82	Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 951-9	13.4	38

81	Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome. <i>Liver International</i> , <b>2008</b> , 28, 249-56	7.9	38
80	Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. <i>Vaccine</i> , <b>2013</b> , 31, 1040-4	4.1	37
79	Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1135-42	19.7	37
78	Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1055-63	19.7	37
77	Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 455-9	13.4	36
76	The cervical spine in rheumatoid arthritis: relationship between neurologic signs and morphology of MR imaging and radiographs. <i>Skeletal Radiology</i> , <b>1996</b> , 25, 113-8	2.7	35
75	Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 666-673	13.4	35
74	Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 689-95	13.4	34
73	Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 1495-502	2.2	33
72	Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 905-913	35.1	33
71	Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. <i>Quality of Life Research</i> , <b>2007</b> , 16, 375-88	3.7	32
70	Immunoglobulin G4-related prostatitis: a case-control study focusing on clinical and pathologic characteristics. <i>Urology</i> , <b>2014</b> , 83, 521-6	1.6	31
69	Viral dynamics in chronic hepatitis B patients during lamivudine therapy. <i>Liver</i> , <b>2002</b> , 22, 121-6		31
68	Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 435-40	13.4	31
67	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 191-6	13.4	30
66	A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 984-91	7	30
65	Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. <i>Scandinavian Journal of Gastroenterology</i> , <b>2006</b> , 41, 1087-94	2.4	30
64	The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. <i>Journal of Hepatology</i> , <b>2002</b> , 37, 253-8	13.4	30

63	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , <b>2015</b> , 64, 322-31	19.2	28
62	Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 100-5	11.6	28
61	Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. <i>Liver International</i> , <b>2007</b> , 27, 1217-25	7.9	28
60	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2076-2084.e2	6.9	27
59	Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. <i>Journal of Vascular Surgery</i> , <b>2009</b> , 50, 687-9	3.5	27
58	Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. <i>BMC Gastroenterology</i> , <b>2010</b> , 10, 144	3	27
57	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , <b>2012</b> , 12, 11	3	26
56	Paired, quantitative measurements of hepatitis B virus DNA in saliva, urine and serum of chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2005</b> , 17, 1173-9	2.2	26
55	Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. <i>Pancreas</i> , <b>2014</b> , 43, 261-7	2.6	25
54	Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 657-67	1.6	24
53	Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1098-1105.e1	6.9	23
52	Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma. <i>Journal of Human Genetics</i> , <b>2012</b> , 57, 26-32	4.3	23
51	Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2523-9	0.7	23
50	Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 1007-11	2.2	23
49	Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage Exchange Arthroplasty: A Multicenter Retrospective Cohort. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz452	1	23
48	Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia. <i>Digestive Diseases and Sciences</i> , <b>2011</b> , 56, 506-12	4	22
47	Is Textbook Outcome a valuable composite measure for short-term outcomes of gastrointestinal treatments in the Netherlands using hospital information system data?. <i>BMJ Open</i> , <b>2018</b> , 8, e019405	3	21
46	Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2449-57	0.7	21

45	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 482-91	13.4	18
44	Neuroenteric peptides affect natural killer activity by intestinal lamina propria mononuclear cells. <i>Journal of Neuroimmunology</i> , <b>1993</b> , 42, 139-45	3.5	18
43	NcoI TNF- $\beta$ gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 378-86	2.4	16
42	Use of visible light spectroscopy to diagnose chronic gastrointestinal ischemia and predict response to treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 122-30.e1	6.9	15
41	Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , <b>2013</b> , 97, 312-7	10.8	15
40	Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution. <i>Statistics in Medicine</i> , <b>2010</b> , 29, 3267-83	2.3	15
39	Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. <i>BMC Gastroenterology</i> , <b>2003</b> , 3, 24	3	15
38	Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 1528-32	7	15
37	Integrity of the anal sphincters after pouch-anal anastomosis: evaluation with three-dimensional endoanal ultrasonography. <i>Diseases of the Colon and Rectum</i> , <b>2005</b> , 48, 1728-35	3.1	15
36	Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 463-472	6.9	15
35	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1546-1557	15.4	14
34	Drug therapies for ulcerative proctitis: systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 2157-78	4.5	13
33	Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1605-8	1.6	13
32	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. <i>Gastroenterology</i> , <b>2018</b> , 155, 1392-1399.e3	13.3	13
31	A comparative study of diagnostic scoring systems for autoimmune pancreatitis. <i>Pancreas</i> , <b>2014</b> , 43, 559-64	2.6	12
30	Heterotopic vs. orthotopic liver transplantation for chronic liver disease: a case-control comparison of short-term and long-term outcomes. <i>Liver Transplantation</i> , <b>2005</b> , 11, 396-401	4.5	12
29	Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1509-1517.e7	6.9	11
28	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon $\alpha$ 2a: progressive decrease in hepatitis B surface antigen in responders. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 1012-9	2.2	10



27	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 684-692.e6	6.9	10
26	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 992-999	13.4	9
25	Renal Dysfunction After Liver Transplantation: Effect of Donor Type. <i>Liver Transplantation</i> , <b>2020</b> , 26, 799-810	4.5	8
24	Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 427-35	1.9	7
23	The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. <i>Transplantation</i> , <b>2020</b> , 104, 2087-2096	1.8	7
22	Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , <b>2007</b> , 45, 258-9	11.2	6
21	Risk stratification and prognostic modelling in primary biliary cholangitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 34-35, 95-106	2.5	5
20	Reproducible radiographs of acetabular prostheses. A method assessed in 35 patients. <i>Acta Orthopaedica</i> , <b>1994</b> , 65, 258-62		5
19	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1688-1697.e14	6.9	5
18	Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients. <i>Clinical Transplantation</i> , <b>2005</b> , 19, 537-42	3.8	4
17	Identification of prosthetic hip and knee joint infections using administrative databases-A validation study. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 42, 325-330	2	4
16	Sustained virological response to treatment in patients with chronic hepatitis C--reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1457	27.4	3
15	Continuous interferon- $\alpha$ 2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 509-17	1.6	3
14	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1451-1458.e4	6.9	3
13	Pediatric Wilson Disease Presenting as Acute Liver Failure: An Individual Patient Data Meta-analysis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2020</b> , 71, e90-e96	2.8	3
12	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2021</b> , 41, 535-544	7.9	3
11	HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 1917-23	19.7	2
10	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1933-1940.e1	6.9	2

9	High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 87-8	3.3	1
8	Effect of blood group and HLA matching on pancreas graft survival with the use of UW solution. <i>Transplant International</i> , <b>1995</b> , 8, 366-73	3	1
7	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 1443-8	2.2	1
6	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 259-261	6.9	1
5	Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. <i>Transplant International</i> , <b>2021</b> , 34, 1444-1454	3	1
4	Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. <i>European Radiology</i> , <b>2022</b> , 32, 67-77	8	1
3	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single-Center Analysis. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1733-1746	4.5	1
2	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 689-698	6.1	0
1	Psychological consequences of MRI-based screening among women with strong family histories of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 497-508	4.4	0